CNR1 Specific Neutra™ Antibody Products

Cannabinoid receptor 1 (CNR1), also known as CB1, is a G protein-coupled receptor (GPCR) primarily found in the central nervous system (CNS), although it is also present in peripheral tissues. CNR1 plays a crucial role in mediating the effects of endocannabinoids, which are lipid signaling molecules that bind to and activate CNR1.

Its Gene ID is 1268, UniProtKB ID is P21554, and OMIM ID is 114610.

CNR1 Pathways

• Endocannabinoid Synthesis and Degradation: CNR1 is involved in the regulation of endocannabinoid synthesis enzymes like NAPE-PLD and FAAH.
• G Protein Signaling: Upon activation by endocannabinoids or exogenous cannabinoids, CNR1 triggers various intracellular signaling cascades through G proteins, including inhibition of adenylate cyclase and modulation of ion channels.
• Retrograde Signaling: CNR1 mediates retrograde synaptic transmission, where endocannabinoids are released from postsynaptic neurons and act on presynaptic CNR1 to regulate neurotransmitter release.

CNR1 Functions

• Modulation of Neurotransmitter Release: Neurotransmitters like glutamate, serotonin, dopamine, and GABA are released under the control of CNR1, which affects neuronal excitability and synaptic transmission.
• Pain Modulation: CNR1 is involved in the modulation of pain perception and analgesia, both centrally and peripherally.
• Appetite Regulation: CNR1 is involved in the control of hunger, food consumption, and energy equilibrium.
• Memory and Learning: CNR1 contributes to the modulation of memory formation and cognitive functions.

CNR1-Related Diseases

• Neurological Disorders: Multiple sclerosis, Parkinson's disease, Alzheimer's disease, and epilepsy have all been linked to dysregulation of CNR1 signaling.
• Psychiatric Disorders: Psychiatric conditions such as anxiety, sadness, schizophrenia, and drug addiction disorders are linked to CNR1 malfunction.
• Metabolic Disorders: CNR1 is involved in the regulation of metabolism and energy balance, and its dysregulation is linked to obesity, metabolic syndrome, and diabetes.

Applications of CNR1 Antibodies

• Research Tools: Antibodies targeting CNR1 enable researchers to conduct detailed analyses through techniques such as Western blotting, immunohistochemistry, and flow cytometry. By using CNR1-specific antibodies, scientists can map the distribution of CNR1 receptors in different physiological and pathological conditions, providing insights into their role in cellular signaling and interaction with endogenous cannabinoids. Additionally, these antibodies can help elucidate the molecular mechanisms underlying cannabinoid receptor-mediated processes, contributing to a deeper understanding of cannabinoid physiology and potential drug targets.
• Diagnostic Applications: CNR1 antibodies can be utilized in diagnostic assays to assess CNR1 expression levels and investigate CNR1 alterations in disease states. For instance, by incorporating CNR1 antibodies into diagnostic protocols, clinicians can detect these changes, aiding in the early diagnosis and progression monitoring of such diseases. Immunohistochemical staining of biopsy samples using CNR1 antibodies can provide visual confirmation of receptor presence and distribution, which can be pivotal in formulating a diagnosis and tailoring personalized treatment strategies.
• Therapeutic Potential: Antibodies targeting CNR1 hold therapeutic potential for modulating CNR1 activity in disease conditions, although further research is needed to explore their efficacy and safety. Monoclonal antibodies against CNR1 could be engineered to enhance or inhibit receptor function, offering a targeted treatment option with potentially fewer side effects compared to traditional small molecule drugs. However, extensive preclinical and clinical studies are required to determine the optimal therapeutic strategies, dosage, and safety profiles for these antibody-based interventions.

Fig.1 Differential CNR signaling modalities influence neuromodulation in health and disease.¹

In summary, Creative Biolabs provides CNR1 antibody products that can be used for cardiovascular and neuroscience research.

REFERENCE

1. Kendall, Debra A., and Guillermo A. Yudowski. "Cannabinoid receptors in the central nervous system: their signaling and roles in disease." Frontiers in cellular neuroscience 10 (2017): 294. Distributed under Open Access license CC BY 4.0. The image was modified by revising the title.